Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery

Three block copolymers added to RESOMER portfolio of bioabsorbable polymers

Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin

Good momentum in commercial CDMO business

Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets

Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets

Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan

Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)

AGC begins study to expand its Bio-CDMO capability in Japan

Syngene full-year revenue from operations up 19% to Rs. 2604 crore

Revenue from operations up 15% to Rs. 758 crore in fourth quarter

AGC to invest $100 million for expanding synthetic pharmaceutical production in Spain

The new facility is scheduled to start operation in the first half of 2024

Evonik restructures health care business

The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries

GenScript wins Best CDMO award for the third time

The award also follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in 2021 for the "Best Contract Development and Manufacturing Organization Award".